
Sign up to save your podcasts
Or


One day you're a team member, and the next day you are the supervisor. How do you handle that position?
These days many sources are highlighting the shocking scale of the global mental health crisis and how this affects approx—a staggering one billion people worldwide - over one-seventh of the global population.
“Unfortunately, as harrowing and monstrous this number is”, the investor Christian Angermayer wrote in a blog post, “it is my belief this is a gross UNDER-estimate.”
Ultimately, the number of people needing mental health support is arguably all 100% of the world's population.
I invited Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, to gain more insights into the unmet medical need in mental health and the promising novel psychedelic drug development sector
Jonathan Sporn MD is a Board Certified Psychiatrist, assistant professor at Columbia University, and CEO of Gilgamesh Pharmaceuticals, based in NYC, which is developing novel psychedelic-related or inspired medicines to treat mental illness.
Topics we discuss in this episode:
➡️ Global Mental Health Situation
➡️ The History of Psychedelic Drug Development
➡️ Investors in this promising area
➡️ The Background Story to the foundation of Gilgamesh Pharmaceutical and
➡️ And the Different Ingredients Needed to Structure a Novel Game-Changing Drug Development Company
Connect with Jonathan Sporn on Linkedin
Youtube Video
🕒 Timestamps:
(00:00) Introduction to Topic, Speaker, and Company
(04:00) Life in New York in 2022
(07:15) The Global Mental Health Pandemic
(10:39) Mass Shootings in the United States as a result of the Mental health Situation
(14:05) Why is it Necessary to Develop Novel Drugs to Fight Mental Health Issues in Society
(19:00) The History of Drug Development for Mental Health Patients
(24:00) How Effective Are Psychedelic Drugs to Tackle Mental Health Questions?
(25:05) Psychedelic Drugs in Pop Culture
(26:40) What Inspired Jonathan Sporn to Dedicate His Professional Life to Advance R&D in Psychedelic Drugs
(29:30) Psychedelic Drugs Help to Observe Own Behaviour
(32:30) Root Causes of Mood Disorders like Maniac Depression, Bipolar Disorder
(34:05) Psychedelic Drugs Enhance Neuroplasticity
(36:50) From Basic Research to Drug Development in the Pharma Industry
(40:10) Mental Health R&D at J&J
(43:40) S-Ketamine vs. K-Ketamine – Difference and Similarities
(46:35) Early-Stage Research in Big Pharma
(49:00) Big Pharma and Small Biotechs
(51:50) The decision to Start A New Company
(57:00) Foundation of Perception Neuroscience – From Early Stage Research to Clinical Phase 2 to Exit
(59:05) Atai Life Science – Continuing Development of the Compounds against Depression
Supporting links:
(01:00:00) Reasons for Becoming a Serial Entrepreneur After a Successful Exit Deal
(01:06:00) Drug Development is Simple – Given an Experienced Drug Development Team
(01:08:00) What is the unique approach of Gilgamesh Pharmaceutical?
(01:10:15) Target Product Profile of Psychedelic Drugs
(01:20:30) Gilgamesh Pharmaceuticals Mission and Vi
Listen on: Apple Podcasts Spotify
Buzzsprout - Let's get your podcast launched!Welcome to another episode of the Rational Reminder Podcast. In today’s jam-packed episode, hear updates regarding our goals survey, the schedule for upcoming guests on the show, the latest news and highlights from the financial world, and some of the feedback we have received about the show. We also highlight interesting articles and papers regarding tech valuations, expected stock returns, the performance of venture capital funds, and a book recommendation that will help you understand the finance game. Tune in to learn about the results of the recent social survey in Canada, the basics of private equity funds, the challenges of calculating the Internal Rate of Returns for investors, some of the misconceptions surrounding private equity, and much more! Don’t miss out on this informative and well-rounded episode of the Rational Reminder Podcast with your two favourite Canadians!
Key Points From This Episode:
View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
Stephan Guyenet is a neuroscientist focused on the neuroscience of obesity and energy homeostasis. He is the author of the book, The Hungry Brain and founder/director of Red Pen Reviews. In this episode, Stephan explains how obesity has changed phenotypically over the course of human history as well as what might explain the dramatic increase in prevalence of obesity in the last few decades. He talks in depth about the role of genetics, the brain, and hormones like leptin play in the regulation of fat mass. He dives deep into two common theories of obesity—the carbohydrate-insulin model and the energy balance model and provides his take on which theory has stronger evidence. Additionally, he provides insights on how we’re hard-wired to think about food and the consequences of modern foods designed for maximal pleasure. Finally, he goes through the factors that affect body weight, set points, and provides takeaways for people wanting to take advantage of what we know about the brain’s role in regulating our body weight.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
From the publisher's feed

16,036 Listeners

3,328 Listeners

1,289 Listeners

539 Listeners

2,697 Listeners

2,448 Listeners

11,772 Listeners

1,092 Listeners

2,200 Listeners

7,983 Listeners

10,183 Listeners

29,190 Listeners

600 Listeners

454 Listeners

142 Listeners